Personalized Medicine Market Reaching Its Adolescence

WASHINGTON – While the intrinsic value of using companion diagnostics to target the right drugs to the right patients is recognized by all components of the health care system, including drugmakers, diagnostic developers, clinician and patient interest groups and payers, more cohesion is needed among all those parties – and at earlier stages in development – for personalized medicine to reach its potential value.